GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arix Bioscience PLC (LSE:ARIX) » Definitions » EV-to-EBIT

Arix Bioscience (LSE:ARIX) EV-to-EBIT : -14.05 (As of May. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Arix Bioscience EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Arix Bioscience's Enterprise Value is £82.78 Mil. Arix Bioscience's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £-5.89 Mil. Therefore, Arix Bioscience's EV-to-EBIT for today is -14.05.

The historical rank and industry rank for Arix Bioscience's EV-to-EBIT or its related term are showing as below:

LSE:ARIX' s EV-to-EBIT Range Over the Past 10 Years
Min: -12.14   Med: -5.2   Max: -3.2
Current: -12.14

During the past 7 years, the highest EV-to-EBIT of Arix Bioscience was -3.20. The lowest was -12.14. And the median was -5.20.

LSE:ARIX's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 10.295 vs LSE:ARIX: -12.14

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Arix Bioscience's Enterprise Value for the quarter that ended in Jun. 2023 was £29.14 Mil. Arix Bioscience's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £-5.89 Mil. Arix Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -20.22%.


Arix Bioscience EV-to-EBIT Historical Data

The historical data trend for Arix Bioscience's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arix Bioscience EV-to-EBIT Chart

Arix Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial -9.73 -7.56 -16.82 -5.28 -5.87

Arix Bioscience Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -5.87 -

Competitive Comparison of Arix Bioscience's EV-to-EBIT

For the Biotechnology subindustry, Arix Bioscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arix Bioscience's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arix Bioscience's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Arix Bioscience's EV-to-EBIT falls into.



Arix Bioscience EV-to-EBIT Calculation

Arix Bioscience's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=82.782/-5.892
=-14.05

Arix Bioscience's current Enterprise Value is £82.78 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arix Bioscience's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £-5.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arix Bioscience  (LSE:ARIX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Arix Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 ) =EBIT / Enterprise Value (Q: Jun. 2023 )
=-5.892/29.135195
=-20.22 %

Arix Bioscience's Enterprise Value for the quarter that ended in Jun. 2023 was £29.14 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arix Bioscience's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £-5.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arix Bioscience EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Arix Bioscience's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Arix Bioscience (LSE:ARIX) Business Description

Traded in Other Exchanges
N/A
Address
50 Duke Street, Duke Street House, London, GBR, W1K 6JL
Arix Bioscience PLC is a healthcare and life science company. Its business model is to source, finance, and develop healthcare and life science businesses that deliver or seek to deliver therapies to patients. Its segment includes sourcing, financing, and developing healthcare and life science businesses globally.

Arix Bioscience (LSE:ARIX) Headlines

No Headlines